552 related articles for article (PubMed ID: 15792920)
1. Erythropoietin use in oncology: a summary of the evidence and practice guidelines comparing efforts of the Cochrane Review group and Blue Cross/Blue Shield to set up the ASCO/ASH guidelines.
Djulbegovic B
Best Pract Res Clin Haematol; 2005; 18(3):455-66. PubMed ID: 15792920
[TBL] [Abstract][Full Text] [Related]
2. The blue cross blue shield assessment technology review: summary of findings.
Bennett CL
Best Pract Res Clin Haematol; 2005; 18(3):423-31. PubMed ID: 15792916
[TBL] [Abstract][Full Text] [Related]
3. The ASH/ASCO clinical guidelines on the use of erythropoietin.
Lichtin A
Best Pract Res Clin Haematol; 2005; 18(3):433-8. PubMed ID: 15792917
[TBL] [Abstract][Full Text] [Related]
4. American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays.
Schrag D; Garewal HS; Burstein HJ; Samson DJ; Von Hoff DD; Somerfield MR;
J Clin Oncol; 2004 Sep; 22(17):3631-8. PubMed ID: 15289488
[TBL] [Abstract][Full Text] [Related]
5. [Summary version of the Standards, Options and Recommendations for the use of recombinant erythropoietin (epoietin-alpha and beta, darbepoietin-alpha, EPO) in the management of anaemia in oncology - Update 2003].
Spaeth D; Casadevall N; Daouphars M; Marchal C; Marec-Berard P; Fabre N; Haugh M;
Bull Cancer; 2004 Feb; 91(2):179-88. PubMed ID: 15047458
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human erythropoietin in cancer-related anemia: an evidence-based review.
Desai J; Demetri GD
Best Pract Res Clin Haematol; 2005; 18(3):389-406. PubMed ID: 15792913
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of erythropoietin in the treatment of patients with malignancies: methods and preliminary results of a Cochrane review.
Bohlius JF; Langensiepen S; Engert A; Schwarzer G; Bennett CL
Best Pract Res Clin Haematol; 2005; 18(3):449-54. PubMed ID: 15792919
[TBL] [Abstract][Full Text] [Related]
8. American Society of Clinical Oncology clinical practice guidelines: opportunities and challenges.
Somerfield MR; Einhaus K; Hagerty KL; Brouwers MC; Seidenfeld J; Lyman GH;
J Clin Oncol; 2008 Aug; 26(24):4022-6. PubMed ID: 18711193
[TBL] [Abstract][Full Text] [Related]
9. [Erythropoietin: a study of its use in oncohematology].
Fernández Martín JM; Villa Rubio A; Cameán Fernández M; Borrero Rubio JM; Martínez Díaz C; Díaz Navarro J; Moreno Sánchez FC; Serrano Ruiz FJ
Farm Hosp; 2004; 28(1):20-8. PubMed ID: 15012175
[TBL] [Abstract][Full Text] [Related]
10. Erythropoietin in the management of patients with nonhematologic cancer receiving chemotherapy. Systemic Treatment Program Committee.
Quirt I; Micucci S; Moran LA; Pater J; Browman G
Cancer Prev Control; 1997 Aug; 1(3):241-8. PubMed ID: 9765749
[TBL] [Abstract][Full Text] [Related]
11. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases.
Mehta MP; Tsao MN; Whelan TJ; Morris DE; Hayman JA; Flickinger JC; Mills M; Rogers CL; Souhami L
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):37-46. PubMed ID: 16111570
[TBL] [Abstract][Full Text] [Related]
12. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
[TBL] [Abstract][Full Text] [Related]
13. [Tumor anemia. Overview of the role of human recombinant erythropoietin (r-hu-EPO) in treatment of tumor anemia].
Monnerat C; Leyvraz S
Praxis (Bern 1994); 1999 Jan; 88(5):178-88. PubMed ID: 10067375
[TBL] [Abstract][Full Text] [Related]
14. Erythropoietin in cancer-related anemia.
Fenner MH; Ganser A
Curr Opin Oncol; 2008 Nov; 20(6):685-9. PubMed ID: 18841051
[TBL] [Abstract][Full Text] [Related]
15. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update.
Bohlius J; Bohlke K; Castelli R; Djulbegovic B; Lustberg MB; Martino M; Mountzios G; Peswani N; Porter L; Tanaka TN; Trifirò G; Yang H; Lazo-Langner A
Blood Adv; 2019 Apr; 3(8):1197-1210. PubMed ID: 30971397
[TBL] [Abstract][Full Text] [Related]
16. American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer.
Basch EM; Somerfield MR; Beer TM; Carducci MA; Higano CS; Hussain MH; Scher HI;
J Clin Oncol; 2007 Nov; 25(33):5313-8. PubMed ID: 17925542
[TBL] [Abstract][Full Text] [Related]
17. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology.
Rizzo JD; Lichtin AE; Woolf SH; Seidenfeld J; Bennett CL; Cella D; Djulbegovic B; Goode MJ; Jakubowski AA; Lee SJ; Miller CB; Rarick MU; Regan DH; Browman GP; Gordon MS;
J Clin Oncol; 2002 Oct; 20(19):4083-107. PubMed ID: 12351606
[TBL] [Abstract][Full Text] [Related]
18. Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policy-guided health care.
Arbuckle RB; Griffith NL; Iacovelli LM; Johnson PE; Jorgenson JA; Kloth DD; Lucarelli CD; Muller RJ
Pharmacotherapy; 2008 May; 28(5 Pt 2):1S-15S. PubMed ID: 18447704
[TBL] [Abstract][Full Text] [Related]
19. Evidence-based medicine, systematic reviews, and guidelines in interventional pain management, part I: introduction and general considerations.
Manchikanti L
Pain Physician; 2008; 11(2):161-86. PubMed ID: 18354710
[TBL] [Abstract][Full Text] [Related]
20. The ASCO experience with evidence-based clinical practice guidelines.
Smith TJ; Somerfield MR
Oncology (Williston Park); 1997 Nov; 11(11A):223-7. PubMed ID: 9430192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
